Astromech, an AI company building predictive models of biology, said on November 17, 2026 that it had acquired Form Bio, which makes AI software for designing genetic medicines. The deal was paid entirely in Astromech stock and was valued at $230 million, according to the announcement, which was datelined Dallas.
Astromech took over Form Bio's intellectual property, its team and a selection of its contracts and assets. Andrew Busey, Form Bio's co-founder and until now its chief executive, became Astromech's chief AI officer and head of technology. Dallas Innovates reported that Form Bio's AI, engineering and product staff were kept on, and that this was Astromech's first acquisition.
The buyer and the seller are closely related. Both came out of Colossal Biosciences, the company best known for its de-extinction projects, and Ben Lamm co-founded all three.
What Form Bio built
Form Bio launched in September 2022 after being developed inside Colossal, with Lamm, Busey and Kent Wakeford as co-founders. Its early work dealt with the computing problems that came up in de-extinction research. It later moved into genetic medicine and genome engineering, building foundation models that learn the structure of regulatory and coding DNA sequences from data.
The company sells tools that help researchers design gene therapies, tune the vectors that deliver them, improve how they are manufactured and check genomic quality. The announcement listed Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences among the groups whose genetic medicine programmes use its software.
Form Bio also cited results from its own projects. In work with Cure Rare Disease on Duchenne muscular dystrophy, redesigning the promoter sequence raised full-genome content from 13% to 59% in under 30 days, and that programme has since moved into in vivo preclinical studies. In a separate programme, changes to the coding sequence alone lifted full-genome content from about 2% to about 45% while expression stayed at its baseline level. These figures come from the company and were not independently verified.
“Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics. Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines.”
Why Astromech is buying
Astromech builds models from genomic and functional data across many species and long stretches of evolutionary time. The aim is to understand how biological functions arose and to predict how they may change. DNA that has stayed the same for hundreds of millions of years can hint at which sequences matter, and those hints can feed into therapeutic design.
Form Bio supplies the design side of that process. The companies said that linking evolutionary insight with design tools should let researchers deal with quality problems earlier, removing unwanted components while a construct is still on the drawing board and possibly reducing the purification work needed later. They named human therapeutics, genome engineering and animal health as the target markets.
Busey said that work with customers had pushed Form Bio from analysing biological data towards helping design genetic medicines. Adrien Savy, director of discovery science at Coave Therapeutics, said the platform was helping his team evaluate and rank gene therapy constructs across several programmes.
The founders and the funding
Form Bio had raised more than $40 million in venture financing, according to the announcement, which did not name its investors or break the total into rounds.
Astromech was co-founded by the geneticist George Church and Lamm and has raised more than $60 million. Dallas Innovates reported that it emerged from stealth in March, had 65 employees and had raised its $60 million by August at a reported valuation of $3.8 billion. The same outlet said Colossal, which Lamm and Church co-founded in 2021, is valued at more than $10 billion.
Reports differed on where the companies are based. The press release was datelined Dallas and said Astromech is headquartered there. Dallas Innovates described both companies as Austin startups in its subheadline while calling Astromech Dallas-based in its article text.
What comes next
The announcement did not say whether Form Bio's software will still be sold under its own name or what changes, if any, existing customers should expect. It also did not say how many Form Bio employees moved to Astromech.
Neither company said who Form Bio's shareholders were or how the $230 million value of the Astromech shares used in the deal was worked out.




